Interferon Alpha Therapy for Cervical CINI and HPV Infection
Status:
Recruiting
Trial end date:
2024-09-15
Target enrollment:
Participant gender:
Summary
Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the
medical care service is not sufficient. In 2000, Mongolian government has developed and
implemented the millennium project in cooperation with WHO. During the years pap smear
analysis of implemented in all rural areas and clinicians, lab technicians have been taught
for the cervical cancer screening. However, the project has finished in 2015 and the rural
and district hospitals has lost the trained professionals. Still the cervical cancer is in
second place after liver cancer in women.
The purpose of the study is to identify the type of HPV genotype and to treat the HPV
infection by local interferon α2b.
Materials and methods: HPV positive patients will be enrolled to the study. HPV genotype will
be determined by the PCR in laboratory. Pap smear will be taken and staged by the CIN.
Pathological tissue will be taken under colposcopy with acetic acid test. Follow up visit
will be done on 10th, 30th days of the treatment.
At the end of 90th days of treatment, pap and histology test will be repeated and CIN
regression or viral eradication will be evaluated.